WO1998052612A1 - Composition antiseptique - Google Patents
Composition antiseptique Download PDFInfo
- Publication number
- WO1998052612A1 WO1998052612A1 PCT/JP1998/002210 JP9802210W WO9852612A1 WO 1998052612 A1 WO1998052612 A1 WO 1998052612A1 JP 9802210 W JP9802210 W JP 9802210W WO 9852612 A1 WO9852612 A1 WO 9852612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- acid
- composition
- hyaluronic acid
- components
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the present invention relates to a method of mixing chlorhexidine dalconate with a water-soluble solution or an aqueous composition containing a drug containing one or more components selected from the group of hyaluronic acid, cromoglycic acid, flavin adenine dinucleotide or a salt thereof.
- the present invention relates to a composition preserved by the above method, a production method thereof and a preservation method.
- At least one component selected from the group consisting of hyaluronic acid, cromoglycic acid, flavin adenine dinucleotide or a salt thereof is useful as a medicament, for example, hyaluronic acid and Z or a salt thereof, particularly an eye drop of sodium hyaluronate, etc.
- aqueous preparations are used, for example, in the ophthalmology field, for healing and preventing damage to the surface of ocular tissues, treating keratosis syndrome, and as an intraocular perfusion solution for intraocular lens injection surgery for cataracts.
- aqueous preparations of sodium hyaluronate are known to be effective in treating osteoarthritis of the knee and periarthritis of the shoulder, and these preparations are also commercially available. These applications are described in U.S. Pat. Nos. 4,141,973 and 4,328,803, JP-A-60-84225, JP-A-31390, JP-A-61-28503, JP-A-11-800044, It is also described in JP-A-246227.
- Sodium cromoglycate is used as a treatment for allergic unilateral asthma and rhinitis, and flavin adenine dinucleotide is used as an eye drop for treatment of keratitis and blepharitis in vitamin B 2 deficiency.
- chlorhexidine dalconate is used as a preservative for aqueous preparations, especially as a preservative for topical aqueous preparations, but when it is added to an aqueous solution of the above-mentioned drugs, an insoluble complex is formed, resulting in cloudiness and the like. It has been considered a contraindication because it occurs. Therefore, chlorhexidine dalconate is not blended with these drugs, and the preservative effect of chlorhexidine gluconate is considered to be hindered if it is blended. Disclosure of the invention
- the present invention contains one or more components selected from the group of hyaluronic acid, cromoglycic acid, flavin adenine dinucleotide or a salt thereof, and is safe and useful having a stable and sufficient antiseptic effect while preventing contraindications for combination. They are trying to provide an aqueous formulation.
- chlorhexidine dalconate which was generally considered to be contraindicated, is blended in an amount that does not produce an insoluble complex, and is stable. They have found that an aqueous preparation having a safe and sufficient antiseptic effect can be obtained, and further studied to complete the present invention.
- the present invention relates to a water-soluble preservative composition containing one or more components selected from the group consisting of hyaluronic acid, cromoglycic acid, flavin adenine dinucleotide or a salt thereof, and chlorhexidine dalconate;
- An aqueous preservative composition comprising an aqueous solution containing chlorhexidine, wherein chlorhexidine dalconate in the aqueous solution does not form an insoluble complex with the same component and has a concentration that maintains the antiseptic effect, and contains the above components.
- a method for preserving an aqueous composition comprising incorporating chlorhexidine dalconate into the aqueous composition to be prepared.
- the concentration of chlorhexidine dalconate in the composition of the present invention varies depending on the type, dosage form and site of administration of the active ingredient, but it is 0 when administered to the mucous membrane in the form of eye drops, ear drops or nasal drops.
- the amount is from 0.01 to 0.05% by weight, preferably from 0.001 to 0.01% by weight, and more preferably about 0.05% by weight.
- the concentration of one or more components selected from the group of hyaluronic acid, cromoglycic acid, flavin adenine dinucleotide or a salt thereof in the composition of the present invention is determined according to the purpose of use of the composition. It is 0.001 to 5% by weight, preferably 0.05 to 3% by weight, and more preferably 0.005 to 1% by weight.
- the composition of the present invention can be administered in the form of various liquids orally or parenterally, and is preferably a topical solution, more preferably an eye drop, an ear drop or a nasal drop.
- composition of the present invention may contain other main ingredients and Z or a component having another kind of medicinal effect, as long as the object of the present invention is not impaired.
- Various additives such as tonicity agents, emulsifiers, thickeners, excipients, dispersants, preservatives, fragrances, solubilizers, solubilizers and solvents are also appropriately used as long as the object of the present invention can be achieved. Is also good.
- composition of the present invention has a ⁇ 51> antimicrobial preservative effectiveness (ANT IMI CROB IAL PRE S ERVAT I VES—EFFECT I VENES S) in a microbial test specified in USP 23. Maintain sufficient preservative efficacy that meets the standards of
- An example of an antiseptic test is as follows.
- R p. 1 is a control using benzalkonium chloride as a preservative.
- Rp. 2 is the formulation of the present invention.
- Example 3 Ophthalmic solution Sodium hyaluronate 0 35 g Boric acid 1 25 g Sodium chloride 0 3 g Chlorhexidine dalconate 0 0025 g Sodium hydroxide
- the above components are dissolved by a conventional method to prepare a nasal solution.
- a concomitant contraindication can be overcome by blending chlorhexidine gluconate with a water-soluble or aqueous composition containing hyaluronic acid, cromoglycic acid or flavin adenine dinucleotide or a salt thereof to overcome the contraindications
- An antiseptic composition is provided that meets these standards.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019997010476A KR20010012521A (ko) | 1997-05-20 | 1998-05-18 | 방부 조성물 |
EP98919660A EP0976407A4 (en) | 1997-05-20 | 1998-05-18 | ANTISEPTIC COMPOSITIONS |
CA002290461A CA2290461A1 (en) | 1997-05-20 | 1998-05-18 | Antiseptic composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14731697 | 1997-05-20 | ||
JP9/147316 | 1997-05-20 | ||
JP10133438A JPH1160505A (ja) | 1997-05-20 | 1998-05-15 | 防腐組成物 |
JP10/133438 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998052612A1 true WO1998052612A1 (fr) | 1998-11-26 |
Family
ID=26467801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/002210 WO1998052612A1 (fr) | 1997-05-20 | 1998-05-18 | Composition antiseptique |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0976407A4 (ja) |
JP (1) | JPH1160505A (ja) |
KR (1) | KR20010012521A (ja) |
CA (1) | CA2290461A1 (ja) |
WO (1) | WO1998052612A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001008489A1 (en) * | 1999-08-02 | 2001-02-08 | Dorn Gordon L | System for stabilizing samples |
US6716632B1 (en) | 1999-08-02 | 2004-04-06 | Gordon L. Dorn | System for stabilizing samples |
WO2019025599A1 (en) | 2017-08-04 | 2019-02-07 | Laboratorios Kin, S.A. | GEL COMPRISING CHLORHEXIDINE |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262020B1 (en) * | 2000-02-15 | 2001-07-17 | Alphamed Pharmaceuticals Corp. | Topical wound therapeutic compositions |
JP4848575B2 (ja) * | 2000-03-30 | 2011-12-28 | ゼリア新薬工業株式会社 | アラントインを配合した安定な液剤 |
DK1142566T3 (da) * | 2000-04-07 | 2004-02-09 | Medidom Lab | Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat |
JP2002037746A (ja) * | 2000-07-24 | 2002-02-06 | Fuji Yakuhin:Kk | キノロンカルボン酸系抗菌剤を含有する液剤 |
AR034371A1 (es) * | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
JP2005187407A (ja) * | 2003-12-25 | 2005-07-14 | Lion Corp | アレルギー眼疾患用眼科組成物 |
JP2005289900A (ja) * | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | クロモグリク酸ナトリウムを含有する液状外用剤 |
WO2006053164A2 (en) * | 2004-11-09 | 2006-05-18 | Advanced Medical Optics, Inc. | Ophthalmic solution |
US8609634B2 (en) | 2007-05-16 | 2013-12-17 | Mcneil-Ppc, Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
US9579341B2 (en) | 2007-05-16 | 2017-02-28 | Johnson & Johnson Consumer Inc. | Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods |
WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
JP2009079032A (ja) * | 2007-09-07 | 2009-04-16 | Lion Corp | 眼科用組成物及びジフェンヒドラミンの安定化方法 |
JP2009073788A (ja) * | 2007-09-21 | 2009-04-09 | Teika Seiyaku Kk | イソプロピルウノプロストン含有眼用組成物 |
JP2013112628A (ja) * | 2011-11-28 | 2013-06-10 | Senju Pharmaceut Co Ltd | 動物用眼科組成物 |
TWI709405B (zh) | 2014-12-25 | 2020-11-11 | 日商參天製藥股份有限公司 | 水性點眼液及其應用 |
SG10201901426WA (en) * | 2015-03-06 | 2019-03-28 | Santen Pharmaceutical Co Ltd | Ophthalmic composition |
WO2016195073A1 (ja) * | 2015-06-05 | 2016-12-08 | 参天製薬株式会社 | 水性点眼液 |
JPWO2021132609A1 (ja) * | 2019-12-27 | 2021-07-01 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0469342A (ja) * | 1990-07-06 | 1992-03-04 | Senju Pharmaceut Co Ltd | 水性医薬製剤 |
JPH08104636A (ja) * | 1993-12-21 | 1996-04-23 | Senju Pharmaceut Co Ltd | 点眼製剤 |
JPH08217678A (ja) * | 1993-12-27 | 1996-08-27 | Senju Pharmaceut Co Ltd | ジフルプレドナート含有点眼用懸濁液剤 |
-
1998
- 1998-05-15 JP JP10133438A patent/JPH1160505A/ja active Pending
- 1998-05-18 WO PCT/JP1998/002210 patent/WO1998052612A1/ja not_active Application Discontinuation
- 1998-05-18 CA CA002290461A patent/CA2290461A1/en not_active Abandoned
- 1998-05-18 KR KR1019997010476A patent/KR20010012521A/ko not_active Application Discontinuation
- 1998-05-18 EP EP98919660A patent/EP0976407A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0469342A (ja) * | 1990-07-06 | 1992-03-04 | Senju Pharmaceut Co Ltd | 水性医薬製剤 |
JPH08104636A (ja) * | 1993-12-21 | 1996-04-23 | Senju Pharmaceut Co Ltd | 点眼製剤 |
JPH08217678A (ja) * | 1993-12-27 | 1996-08-27 | Senju Pharmaceut Co Ltd | ジフルプレドナート含有点眼用懸濁液剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0976407A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001008489A1 (en) * | 1999-08-02 | 2001-02-08 | Dorn Gordon L | System for stabilizing samples |
US6716632B1 (en) | 1999-08-02 | 2004-04-06 | Gordon L. Dorn | System for stabilizing samples |
US6946297B2 (en) | 1999-08-02 | 2005-09-20 | Dorn Gordon L | System for stabilizing samples |
WO2019025599A1 (en) | 2017-08-04 | 2019-02-07 | Laboratorios Kin, S.A. | GEL COMPRISING CHLORHEXIDINE |
Also Published As
Publication number | Publication date |
---|---|
EP0976407A1 (en) | 2000-02-02 |
JPH1160505A (ja) | 1999-03-02 |
KR20010012521A (ko) | 2001-02-15 |
CA2290461A1 (en) | 1998-11-26 |
EP0976407A4 (en) | 2001-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998052612A1 (fr) | Composition antiseptique | |
US5110493A (en) | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant | |
US5414011A (en) | Preservative system for ophthalmic formulations | |
EP1399127A1 (en) | Olopatadine formulations for topical administration | |
AU2002310461A1 (en) | Olopatadine formulations for topical administation | |
EP2002841A1 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
JP2004514731A (ja) | 眼薬送達のための可逆的ゲル化システム | |
US20070128156A1 (en) | Ophthalmic compositions containing a synergistic combination of two polymers | |
US6281224B1 (en) | Pranoprofen eyedrops containing organic amine | |
JPH11240838A (ja) | アジスロマイシンによる眼感染症の治療法 | |
JP2003206241A (ja) | 眼科用剤 | |
EP1283043B1 (en) | Ophthalmic solution | |
JP2916340B2 (ja) | ナトリウムクロモグリケートの水性医薬組成物 | |
JPH115744A (ja) | ヒアルロン酸含有の外用水溶液製剤 | |
JPH03118321A (ja) | 透明且つ安定なクロモリン剤 | |
JP4325129B2 (ja) | 防腐剤 | |
PT90356B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo solucoes aquosas de pentamidina | |
JP4801300B2 (ja) | 外用液状組成物 | |
JP4442118B2 (ja) | 安定な点眼剤 | |
JP5013735B2 (ja) | 眼粘膜適用製剤 | |
CA2413088C (en) | Preservative | |
JP4157988B2 (ja) | 配合禁忌の防止された水溶性製剤 | |
JP4813682B2 (ja) | 眼科用剤 | |
JP4524538B2 (ja) | 眼科用組成物 | |
KR100430428B1 (ko) | 설린닥을 함유하는 망막 손상 치료용 안약 조성물과 그제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09423508 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997010476 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2290461 Country of ref document: CA Ref country code: CA Ref document number: 2290461 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998919660 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919660 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997010476 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998919660 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019997010476 Country of ref document: KR |